|
1
|
Porche D: Prostate cancer: Overview of
screening, diagnosis and treatment. Adv NPs PAs. 2:18–21; quiz 22.
2011.PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Laversanne M, Brewster
DH, Mbalawa C Gombe, Kohler B, Piñeros M, Steliarova-Foucher E,
Swaminathan R, Antoni S, et al: Cancer incidence in five
continents: Inclusion criteria, highlights from volume X and the
global status of cancer registration. Int J Cancer. 137:2060–2071.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hussain S, Haidar A, Bloom RE, Zayouna N,
Piper MH and Jafri SM: Bicalutamide-induced hepatotoxicity: A rare
adverse effect. Am J Case Rep. 15:266–270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone
C, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a
high CD8+/regulatory T cell ratio are associated with favorable
prognosis in ovarian cancer. Proc Natl Acad Sci USA.
102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within
cancer cell nests as a prognostic factor in human colorectal
cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
10
|
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert C, Ribas A, Wolchok JD, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schadendorf D, Hodi FS, Robert C, Weber
JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM and Wolchok JD:
Pooled analysis of long-term survival data from Phase II and Phase
III trials of ipilimumab in unresectable or metastatic melanoma. J
Clin Oncol. 33:1889–1894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minn AJ and Wherry EJ: Combination cancer
therapies with immune checkpoint blockade: Convergence on
interferon signaling. Cell. 165:272–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galsky MD, Noah H, Starodub A, Hauke RJ,
Twardowski P, Fleming M, Qi J, Sonpavde G, Patel M, Zhu J, et al:
Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on
circulating immune cells in patients with metastatic bladder
cancer. J Immunother Cancer. 3:(Suppl 2). P2572015. View Article : Google Scholar :
|
|
16
|
Zamarin D and Postow MA: Immune checkpoint
modulation: Rational design of combination strategies. Pharmacol
Ther. 150:23–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao X, He Y, Gao J, Fan L, Li Z, Yang G
and Chen H: Caveolin-1 expression level in cancer associated
fibroblasts predicts outcome in gastric cancer. PLoS One.
8:e591022013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eastwood D, Findlay L, Poole S, Bird C,
Wadhwa M, Moore M, Burns C, Thorpe R and Stebbings R: Monoclonal
antibody TGN1412 trial failure explained by species differences in
CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol.
161:512–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mittler RS, Foell J, McCausland M,
Strahotin S, Niu L, Bapat A and Hewes LB: Anti-CD137 antibodies in
the treatment of autoimmune disease and cancer. Immunol Res.
29:197–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kolar P, Knieke K, Hegel JK, Quandt D,
Burmester GR, Hoff H and Brunner-Weinzierl MC: CTLA-4 (CD152)
controls homeostasis and suppressive capacity of regulatory T cells
in mice. Arthritis Rheum. 60:123–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Philips GK and Atkins M: Therapeutic uses
of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 27:39–46.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Berthold DR, Pond GR, Soban F, de Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: Updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galsky MD and Vogelzang NJ:
Docetaxel-based combination therapy for castration-resistant
prostate cancer. Ann Oncol. 21:2135–2144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh RP and Agarwal R: Prostate cancer
chemoprevention by silibinin: Bench to bedside. Mol Carcinog.
45:436–442. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boxberger F, Albrecht H, Konturek PC,
Reulbach U, Maennlein G, Meyer T, Hohenberger W, Hahn EG and Wein
A: Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a
24 h-infusion, folinic acid and biweekly oxaliplatin in patients
with primary resectable liver metastases of colorectal cancer:
Long-term results of a phase II trial. Med Sci Monit. 16:CR49–CR55.
2010.PubMed/NCBI
|
|
28
|
Zhang K, Qin H, Pan F, Liu E, Liang H and
Ruan Z: Nedaplatin or oxaliplatin combined with paclitaxel and
docetaxel as first-line treatment for patients with advanced
non-small cell lung cancer. Med Sci Monit. 20:2830–2836. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Droz JP, Muracciole X, Mottet N, Kaci M
Ould, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL,
Mackenzie S, et al: Phase II study of oxaliplatin versus
oxaliplatin combined with infusional 5-fluorouracil in hormone
refractory metastatic prostate cancer patients. Ann Oncol.
14:1291–1298. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dorff TB, Tsao-Wei DD, Groshen S, Boswell
W, Goldkorn A, Xiong S, Quinn DI and Pinski JK: Efficacy of
oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic
castration-resistant prostate cancer. Clin Genitourin Cancer.
11:416–422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shan B, Ma F, Wang M and Xu X:
Down-regulating receptor interacting protein kinase 1 (RIP1)
promotes oxaliplatin-induced Tca8113 cell apoptosis. Med Sci Monit.
21:3089–3094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horwitz DA, Zheng SG, Wang J and Gray JD:
Critical role of IL-2 and TGF-beta in generation, function and
stabilization of Foxp3+CD4+ Treg. Eur J Immunol. 38:912–915. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nanki T and Lipsky PE: Stimulation of
T-Cell activation by CXCL12/stromal cell derived factor-1 involves
a G-protein mediated signaling pathway. Cell Immunol. 214:145–154.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Whitmire JK, Tan JT and Whitton JL:
Interferon-gamma acts directly on CD8+ T cells to increase their
abundance during virus infection. J Exp Med. 201:1053–1059. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu S, Zhang N, Yopp AC, Chen D, Mao M,
Chen D, Zhang H, Ding Y and Bromberg JS: TGF-beta induces Foxp3 +
T-regulatory cells from CD4+ CD25- precursors. Am J Transplant.
4:1614–1627. 2004. View Article : Google Scholar : PubMed/NCBI
|
